The convergence of cancer prevention and therapy in early-phase clinical drug development.


Journal Article (Review)

After decades of separate but not equal drug development, prevention and therapy are beginning to converge at the level of early-phase clinical testing. This highly beneficial convergence is due to spectacular molecular advances in our understanding of neoplasia (both cancer and precancer), cancer risk and prognosis, and the mechanisms by which novel drugs with less toxicity and more cytostatic activity profiles target specific molecular events to suppress malignant and premalignant cells. The future full convergence of prevention-therapy drug development (aided by technological advances, such as in molecular imaging) promises to hasten the progress of oncology in reducing the public health impact of the major cancers.

Full Text

Duke Authors

Cited Authors

  • Abbruzzese, JL; Lippman, SM

Published Date

  • October 2004

Published In

Volume / Issue

  • 6 / 4

Start / End Page

  • 321 - 326

PubMed ID

  • 15488755

Pubmed Central ID

  • 15488755

International Standard Serial Number (ISSN)

  • 1535-6108

Digital Object Identifier (DOI)

  • 10.1016/j.ccr.2004.09.021


  • eng

Conference Location

  • United States